Paliperidone ER-Lurasidone

From Psychiatrienet
Revision as of 16:09, 18 March 2022 by Ken (talk | contribs) (Created page with "<big><span style="color:#ff0000"> * This switch is intended for paliperidone long acting (Xeplion®, 30 days) </span></big> {{Drugswitch | from = Paliperidone LA | to = Lura...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

* This switch is intended for paliperidone long acting (Xeplion®, 30 days)

Paliperidone
long acting
Type Antipsychotic
Group Atypical AP
links
Medscape Paliperidone
PubChem 23724979
PubMed Paliperidone
Kompas (Dutch) Paliperidone
Wikipedia Paliperidone
Lurasidone
Type Antipsychotic
Group Atypical AP
links
Medscape Lurasidone
PubMed Lurasidone
Kompas (Dutch) Lurasidone
Wikipedia Lurasidone

Switch medication from Paliperidone LA to Lurasidone.[1] [2]

Nietinrijdenbord.png Stop Paliperidone LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Lurasidone
  • Week 1-3: approx. 25% of target dose
  • Week 4-6: approx. 50% of target dose
  • Week 7-9: approx. 75% of target dose
  • Week 10: target dose
Infobord.png More information
  • More information on switching to lurasidon: see reference. [3]
    StopDepotStartOral.jpg
Nietinrijdenbord.png — Paliperidone LA
Eenrichtingbord.png — Lurasidone


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. McEvoy JP et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.J Clin Psychiatry. 2013 Feb;74(2):170-9.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.